NCT01336478

CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation

Safety and Toxicity of Escalating Doses of Adoptively Infused ex Vivo Selected CD56+CD3- NK Cells on Day 7 Following Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies.

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Imperial College London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The investigators propose a nonrandomized, Phase I study to assess the safety of infusion of NK cells that will be selected from sibling donors and infused to patients with hematological malignancies early following allogeneic stem cell transplantation.

Detailed description

Allogeneic hematopoietic stem cell transplantation (HSCT) is a very effective treatment for a number of hematological malignancies but relapse remains a major problem, especially in patients with high risk disease. Natural killer (NK) cells are immune cells that recognize and kill virally infected cells and tumor cells. NK cells are identified by the expression of the CD56 surface antigen and the lack of CD3. Their ability to kill tumor cells makes them promising to evaluate as effector cells for immunotherapy.

Conditions

• Haematological Malignancies
• Allogeneic Stem Cell Transplant
• CD56+CD3- NK Cells

Interventions

Type	Name	Description
PROCEDURE	Infusion of donor derived ex-vivo selected NK cells to patients after transplant	Infusion of donor derived ex-vivo selected NK cells to patients after transplant
PROCEDURE	Haematology / Blood chemistry sampling	Haematology / Blood chemistry sampling, collection of blood for ancillary lab research

Timeline

• Start date: 2011-04-01
• Primary completion: 2014-06-01
• Completion: 2014-06-01
• First posted: 2011-04-18
• Last updated: 2015-06-08

Locations

1 site across 1 country: United Kingdom